Myriad Genetics, Inc. splits its revenue into 5 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Cancer Care Continuum at $114.1 million, 60% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
807
|
191
|
200
|
210
|
206
|
213
|
196
|
211
|
213
|
| Cancer Care Continuum |
—
|
114
share 59.8%
|
120
+4.0%
share 60.0%
|
—
|
—
|
—
|
116
share 59.0%
|
—
|
—
|
| Hereditary Cancer Testing |
—
|
—
|
—
|
—
|
93
+2.8%
share 45.2%
|
96
share 45.2%
|
—
|
—
|
90
share 42.4%
|
| Prenatal Health |
—
|
40
-16.4%
share 20.9%
|
42
-15.0%
share 20.9%
|
—
|
44
+2.3%
share 21.6%
|
48
share 22.3%
|
49
share 25.2%
|
—
|
44
share 20.4%
|
| Mental Health |
—
|
37
-2.6%
share 19.3%
|
38
+23.5%
share 19.1%
|
37
-9.9%
share 17.4%
|
39
-18.9%
share 18.8%
|
38
share 17.7%
|
31
share 15.8%
|
41
share 19.3%
|
48
share 22.4%
|
| Tumor Profiling |
—
|
—
|
—
|
32
+2.6%
share 15.0%
|
30
-6.6%
share 14.3%
|
31
share 14.7%
|
—
|
31
share 14.6%
|
32
share 14.8%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.